Using breath and skin tests to detect melanoma early

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness of non-invasive technologies, specifically a breath analyzer and a skin patch, in detecting metastatic melanoma through the analysis of volatile organic compounds (VOCs). Over a period of 24 months, the study will compare the results from these devices with standard imaging techniques and correlate them with established prognostic biomarkers obtained via liquid biopsy. The goal is to identify patterns in VOCs that could indicate the presence of metastases in melanoma patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Be over 18 years old
* Have a histopathological confirmed melanoma diagnosis (stage II, III or IV AJCC)

Exclusion Criteria:

* Not signing the informed consent form
* Present other cancers or chronic diseases (such as diabetes, asthma, etc.), which may affect the volatile organic compound profiles

Where it's running

• Hospital Clínic Barcelona
  Barcelona, Spain Recruiting
• Hospital Clínic Barcelona
  Barcelona, Spain Recruiting
• Hospital Clínic de Barcelona (Dermatology service)
  Barcelona, Spain Not yet recruiting

Study contacts

• Study coordinator: Susana Puig Sardà, PhD, MD
• Email: spuig@clinic.cat
• Phone: +34932275400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Creating a database for melanoma in children and young adults

  This study is trying to create a detailed database for melanoma in kids and young adults to see how well they do and improve treatment options for them.

  Recruiting Fundacion Clinic per a la Recerca Biomédica · Barcelona, Catalonia · NCT06608420

• PD-L1-targeted PET probe to map PD-L1 in solid tumors

  A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing · NCT07848243

• ctDNA-guided stopping of immune therapy in advanced melanoma

  This study tests whether stopping immune checkpoint inhibitor therapy after 12 months is safe for patients with advanced melanoma who have undetectable ctDNA and disease control.

  Recruiting Rutgers, The State University of New Jersey · New Brunswick, New Jersey · NCT07830225

• ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients

  This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.

  Recruiting at 2 sites Tam Anh Research Institute · Hanoi, Hanoi and 1 other locations · NCT07808164

• 68Ga-SorB PET/CT imaging for solid tumors

  This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07760012

• NeoAdjuvant PD-1–Based Therapy in Resectable Advanced Melanoma (NASA)

  In people with resectable stage IIIB–IV melanoma, this study tests whether two infusions of pembrolizumab or a combination of ipilimumab plus nivolumab given before surgery can keep people alive at 2 years without needing additional adjuvant therapy.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07740941

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.